| Today’s Big NewsOct 29, 2024 |
| By Nick Paul Taylor Novartis’ 2.7 billion euro gamble on MorphoSys has hit turbulence. Months after buying the biotech, Novartis has revealed a safety signal that could set back plans to seek approval for the jewel of the acquisition by a couple of years. |
|
|
|
By James Waldron Pfizer’s respiratory syncytial virus (RSV) pipeline appears to have run dry of candidates following the cessation of work on both an oral medicine and an RSV-flu combo vaccine in quick succession. |
By James Waldron Not content with getting the first lupus drug to market in the form of the blockbuster Benlysta, GSK is handing over $300 million in upfront cash for a clinical-stage T-cell engager it believes could target patients who aren’t benefiting from current treatments. |
Sponsored by Questex Fierce Biotech sits down with digital marketing leaders to discuss this year's most innovative topics at Fierce Biotech Summit and New Product Planning |
|
| 45 markers for cytokine signaling/inflammationTrust RBM for Olink, Luminex & Simoa immunoassays
|
|
By Nick Paul Taylor Crescent Biopharma has landed a Nasdaq listing in a reverse merger with GlycoMimetics and secured $200 million to support its pursuit of the white-hot PD-1xVEGF bispecific opportunity. GlycoMimetics took the deal, which gives its shareholders 3.1% of the combined company, after reporting a phase 2/3 failure. |
Sponsored by Turbine.Ai Join us on the latest Top Line podcast as we dive into how Turbine Simulated Cell Technologies is reshaping drug development. Discover their innovative approaches to combatting biases in data, leading to more effective cancer treatments. Tune in now! |
By James Waldron Two years after Idorsia and Neurocrine’s calcium channel blocker flunked a pair of phase 2 studies in quick succession, the biotechs have finally decided to part ways. |
By Nick Paul Taylor An investigator has posted data on Coya Therapeutics’ COYA 301, linking the IL-2 asset to improvements in biomarkers and cognition on secondary and exploratory endpoints in a small Alzheimer’s disease trial. The biotech put the asset on the backburner last year but said the data boost its confidence in pursuing partnerships and studying drug combinations. |
By James Waldron Innovent has posted another psoriasis win for its IL-23 contender to the likes of Tremfya and Skyrizi while the company awaits an approval decision by Chinese regulators. |
By Fraiser Kansteiner Korea's GemVax revealed Tuesday that its peptide drug candidate GV1001 missed the mark in a phase 2a study in progressive supranuclear palsy (PSP). PSP is a degenerative disease, not unlike Parkinson’s disease, that leads to symptoms like gait disturbances, early falls, vertical gaze palsy, rigidity, tremors and cognitive decline. |
By Gabrielle Masson On the heels of a phase 3 win that failed to impress investors, Ironwood Pharmaceuticals is back with more data in efforts to prove that its long-acting GLP-2 analog can do more than beat placebo. |
By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Fraiser Kansteiner EyePoint released new diabetic macular edema data Monday that a Mizuho Securities analyst described as "very promising." The trial win provides a needed turnaround for the company's lead candidate Duravyu, which failed a study in nonproliferative diabetic retinopathy earlier this year. |
By Paige Minemyer Employers are concerned that rising healthcare costs could force them to rethink salary or wage increases, according to a new study. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Medtech's Conor Hale dives into EY's 18th annual Pulse of the MedTech Industry report and chats with EY's John Babbitt about the team's findings and the pace of M&A, venture capital funding and recent IPOs. |
|
|---|
|
|
|
Wednesday, November 6, 2024 | 1pm ET / 10am PT Generative AI models help scientists better understand proteins, small molecules, DNA, biomedical text, and more. But building, training, and deploying these models can be complex. Join us to discuss the benefits of moving to the cloud to accelerate drug discovery pipelines, and why using customized AI models can help you get to market faster. Register now.
|
|
| WhitepaperUnlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
| WhitepaperDiscover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
| eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
| WhitepaperTake a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
